September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Leber's hereditary Optic Neuropathy: repurposing FDA-approved molecules to identify potential leads.
Author Affiliations & Notes
  • Sandipan Datta
    Molecular Biosciences, University of California Davis, Davis, California, United States
  • Gino Cortopassi
    Molecular Biosciences, University of California Davis, Davis, California, United States
  • Footnotes
    Commercial Relationships   Sandipan Datta, None; Gino Cortopassi, None
  • Footnotes
    Support  NEI grant R01 EY012245
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1112. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sandipan Datta, Gino Cortopassi; Leber's hereditary Optic Neuropathy: repurposing FDA-approved molecules to identify potential leads.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1112.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Leber's hereditary Optic Neuropathy (LHON) is one of the commonest inherited mitochondrial diseases, in which mitochondrial complex 1 mutations cause optic atrophy and vision loss. Currently there is no FDA-approved therapy for LHON and few ongoing clinical trials. We took a repurposing approach to LHON by screening FDA-approved drugs for their ability to rescue a LHON-specific cellular defect.

Methods : We determined a LHON-dependent defect in mitochondrial complex 1-driven ATP synthesis, that could be assayed in high throughput using the human osteosarcoma LHON cellular hybrids (Z' ≥ 0.4). We screened a FDA-approved small-molecule drug library of 1600 drugs though this assay in duplicate. The hits identified were reconfirmed in a concentration-dependent response in the same assay.

Results : A LHON-specific defect in complex I-dependent ATP synthesis was determined, and this biochemical parameter was reduced in cells bearing the three commonest LHON mutations, 11778, 3460, and 14484, in proportion to their severity. Then, 1600 drugs were screened in an optimized high-throughput assay for their effect to rescue this parameter in 11778(G>A) cells, to identify 34 protective molecules. Of those 34, 2 were consistently protective in six-point concentration-response curves. These drugs rescued complex-1 driven ATP synthesis both in mutants and controls. Mechanistic experiments suggested a mechanism related to the cyclic AMP pathway.

Conclusions : LHON mutations can cause defects in mitochondrial complex 1-mediated ATP synthesis under stress, which can be rescued at the cellular level. Thus, these are the first-ever drugs to rescue a LHON-specific defect in cells, and the first-ever demonstration of a small molecule that increases complex-I driven ATP synthesis. Tests in animal models of LHON are the next step to support or refute their therapeutic potential.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×